Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
← catalyst calendarNCT07064759 · readout ≤ 834 d
Sponsored by 4D Molecular Therapeutics (industry) · FDMT — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
480estimated
Sites
94
Countries
Argentina, Australia, Bulgaria +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-22 | actual | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
- Biological: 4D-150 IVT (3E10 vg/eye)
- Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52
measured 52 Weeks
Permalink · FDMT's whole pipeline · Catalyst calendar · Every registered study · What changed